<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089674</url>
  </required_header>
  <id_info>
    <org_study_id>20040138</org_study_id>
    <secondary_id>HALT Prostate Cancer</secondary_id>
    <nct_id>NCT00089674</nct_id>
  </id_info>
  <brief_title>AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing
      Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36</measure>
    <time_frame>36 months</time_frame>
    <description>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36</measure>
    <time_frame>36 months</time_frame>
    <description>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36</measure>
    <time_frame>36 months</time_frame>
    <description>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Fracture Through Month 36</measure>
    <time_frame>36 months</time_frame>
    <description>Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a New Vertebral Fracture Through Month 36</measure>
    <time_frame>36 months</time_frame>
    <description>New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Clinical Fracture Through Month 36</measure>
    <time_frame>36 months</time_frame>
    <description>A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Fracture Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1468</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>AMG 162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 162</intervention_name>
    <description>60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30</description>
    <arm_group_label>AMG 162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Other criteria also apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Egerdie RB, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):308-12.</citation>
    <PMID>22641239</PMID>
  </reference>
  <reference>
    <citation>Lippuner k, Wolff JM, Hadji P, Braun A, Ke C, Steinle T, Eisen C. Risk reduction for vertebral fractures in patients with normal to osteopenic bone mineral density receiving denosumab: A subgroup analysis of the HALT Prostate Cancer Trial. Osteologie 2014;23(2):117-122. [published in German only]</citation>
  </reference>
  <reference>
    <citation>Smith MR, Egerdie B, Hern√°ndez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.</citation>
    <PMID>19671656</PMID>
  </reference>
  <reference>
    <citation>Smith MR, Saad F, Egerdie B, Sieber P, Tammela TLj, Leder BZ, Ke C, Goessl C. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011 Dec;26(12):2827-33. doi: 10.1002/jbmr.492.</citation>
    <PMID>21898590</PMID>
  </reference>
  <reference>
    <citation>Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009 Dec;182(6):2670-5. doi: 10.1016/j.juro.2009.08.048.</citation>
    <PMID>19836774</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2004</study_first_submitted>
  <study_first_submitted_qc>August 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2004</study_first_posted>
  <results_first_submitted>July 2, 2010</results_first_submitted>
  <results_first_submitted_qc>May 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2014</results_first_posted>
  <disposition_first_submitted>November 23, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2009</disposition_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Bone Loss with Prostate Cancer</keyword>
  <keyword>Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject Enrolled: 15-Apr-2004 Last Subject Enrolled: 29-Apr-2005</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo administered subcutaneous every 6 months for 3 years</description>
        </group>
        <group group_id="P2">
          <title>Denosumab 60 mg Q6M</title>
          <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="734"/>
                <participants group_id="P2" count="734"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="730"/>
                <participants group_id="P2" count="726"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="267"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo administered subcutaneous every 6 months for 3 years</description>
        </group>
        <group group_id="B2">
          <title>Denosumab 60 mg Q6M</title>
          <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="734"/>
            <count group_id="B2" value="734"/>
            <count group_id="B3" value="1468"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.5" spread="7.1"/>
                    <measurement group_id="B2" value="75.3" spread="7"/>
                    <measurement group_id="B3" value="75.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="734"/>
                    <measurement group_id="B2" value="734"/>
                    <measurement group_id="B3" value="1468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="609"/>
                    <measurement group_id="B2" value="615"/>
                    <measurement group_id="B3" value="1224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24</title>
        <description>Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 24. LOCF used as imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24</title>
          <description>Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 24. LOCF used as imputation method.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="716"/>
                <count group_id="O2" value="714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-1.4" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5.3" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.2</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24</title>
        <description>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 24. LOCF used as imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24</title>
          <description>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 24. LOCF used as imputation method.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="706"/>
                <count group_id="O2" value="701"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-1.8" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.1" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.5</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24</title>
        <description>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 24. LOCF used as imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24</title>
          <description>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 24. LOCF used as imputation method.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="706"/>
                <count group_id="O2" value="701"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-2.3" upper_limit="-1.8"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.4</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36</title>
        <description>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>36 months</time_frame>
        <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 36. LOCF used as imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36</title>
          <description>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 36. LOCF used as imputation method.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="716"/>
                <count group_id="O2" value="714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-1.5" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="6.4" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.4</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36</title>
        <description>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>36 months</time_frame>
        <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 36. LOCF used as imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36</title>
          <description>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 36. LOCF used as imputation method.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="706"/>
                <count group_id="O2" value="701"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-2.2" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="3" lower_limit="2.7" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.4</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36</title>
        <description>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>36 months</time_frame>
        <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 36. LOCF used as imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36</title>
          <description>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Randomized subjects who had a nonmissing baseline and &gt;= 1 nonmissing postbaseline data before or at month 36. LOCF used as imputation method.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="706"/>
                <count group_id="O2" value="701"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-2.8" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.9" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.4</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Fracture Through Month 36</title>
        <description>Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.</description>
        <time_frame>36 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Fracture Through Month 36</title>
          <description>Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="734"/>
                <count group_id="O2" value="734"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1048</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a New Vertebral Fracture Through Month 36</title>
        <description>New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.</description>
        <time_frame>36 months</time_frame>
        <population>All randomized subjects who have a baseline and &gt;= 1 postbaseline evaluation of vertebral fracture at or before 3 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a New Vertebral Fracture Through Month 36</title>
          <description>New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.</description>
          <population>All randomized subjects who have a baseline and &gt;= 1 postbaseline evaluation of vertebral fracture at or before 3 years.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="673"/>
                <count group_id="O2" value="679"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Clinical Fracture Through Month 36</title>
        <description>A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.</description>
        <time_frame>36 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Clinical Fracture Through Month 36</title>
          <description>A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="734"/>
                <count group_id="O2" value="734"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7961</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Fracture Through Month 24</title>
        <description>Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.</description>
        <time_frame>24 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneous every 6 months for 3 years</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Fracture Through Month 24</title>
          <description>Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="734"/>
                <count group_id="O2" value="734"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7961</p_value>
            <p_value_desc>Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <desc>Five participants randomized to placebo received 1 dose of denosumab in error and are included in the denosumab group for safety analysis. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo administered subcutaneous every 6 months for 3 years</description>
        </group>
        <group group_id="E2">
          <title>Denosumab 60 mg Q6M</title>
          <description>Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="253" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Retinal vascular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Leukoplakia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pancreatitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Peritoneal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bursitis infective staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastrointestinal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Failure of implant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Nerve root injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pacemaker complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Stenosis of vesicourethral anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Joint lock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Malignant glioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cerebrovascular spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Contracted bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ureteric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Kidney ablation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="364" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="390" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="731"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="725"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="731"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

